Abpro Holdings, Inc. (ABP)
| Market Cap | 77.30M |
| Revenue (ttm) | 122,000 |
| Net Income (ttm) | -16.26M |
| Shares Out | 50.52M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,481 |
| Open | 1.670 |
| Previous Close | 1.600 |
| Day's Range | 1.520 - 1.750 |
| 52-Week Range | 1.410 - 13.000 |
| Beta | -0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 3, 2025 |
About ABP
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. Abpro Holdings, Inc. was incorporated in 2004 and is... [Read more]
Financial Performance
In 2023, Abpro Holdings's revenue was $122,000, a decrease of -93.99% compared to the previous year's $2.03 million. Losses were -$11.71 million, -32.00% less than in 2022.
Financial StatementsNews
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening di...